Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis.

Ellenberger D, Eichstädt K, Flachenecker P, Friede T, Haas J, Kleinschnitz C, Pöhlau D, Rienhoff O, Stahmann A, Zettl UK, Rommer PS.

Mult Scler Relat Disord. 2018 Jul 24;25:173-174. doi: 10.1016/j.msard.2018.07.040. [Epub ahead of print] No abstract available.

PMID:
30096682
2.

Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.

Metze C, Winkelmann A, Loebermann M, Hecker M, Schweiger B, Reisinger EC, Zettl UK.

CNS Neurosci Ther. 2018 Jul 25. doi: 10.1111/cns.13034. [Epub ahead of print]

PMID:
30044050
3.

Microarray data of transcriptome shifts in blood cell subsets during S1P receptor modulator therapy.

Koczan D, Fitzner B, Zettl UK, Hecker M.

Sci Data. 2018 Jul 24;5:180145. doi: 10.1038/sdata.2018.145.

4.

Intravenous immunoglobulin treatment in multiple sclerosis: A prospective, rater-blinded analysis of relapse rates during pregnancy and the postnatal period.

Winkelmann A, Rommer PS, Hecker M, Zettl UK.

CNS Neurosci Ther. 2018 Jun 1. doi: 10.1111/cns.12985. [Epub ahead of print]

PMID:
29858532
5.

Applying the 2017 McDonald diagnostic criteria for multiple sclerosis.

Rommer PS, Zettl UK.

Lancet Neurol. 2018 Jun;17(6):497-498. doi: 10.1016/S1474-4422(18)30161-3. No abstract available.

PMID:
29778357
6.

The sphingosine analog fingolimod (FTY720) enhances tone and contractility of rat gastric fundus smooth muscle.

Kraft M, Zettl UK, Noack T, Patejdl R.

Neurogastroenterol Motil. 2018 May 8:e13372. doi: 10.1111/nmo.13372. [Epub ahead of print]

PMID:
29740911
7.

Coping behavior in multiple sclerosis-complementary and alternative medicine: A cross-sectional study.

Rommer PS, König N, Sühnel A, Zettl UK.

CNS Neurosci Ther. 2018 Apr 10. doi: 10.1111/cns.12857. [Epub ahead of print]

PMID:
29635832
8.

Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis.

Mueller SH, Färber A, Prüss H, Melzer N, Golombeck KS, Kümpfel T, Thaler F, Elisak M, Lewerenz J, Kaufmann M, Sühs KW, Ringelstein M, Kellinghaus C, Bien CG, Kraft A, Zettl UK, Ehrlich S, Handreka R, Rostásy K, Then Bergh F, Faiss JH, Lieb W, Franke A, Kuhlenbäumer G, Wandinger KP, Leypoldt F; German Network for Research on Autoimmune Encephalitis (GENERATE).

Ann Neurol. 2018 Apr;83(4):863-869. doi: 10.1002/ana.25216.

PMID:
29572931
9.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541. [Epub ahead of print]

PMID:
29532745
10.

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Rommer PS, Zettl UK.

Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Review.

PMID:
29528247
11.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

12.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.

Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, Nazarov V, Lapin S, Midaglia L, Vidal-Jordana A, Drulovic J, García-Merino A, Sánchez-López AJ, Havrdova E, Saiz A, Llufriu S, Alvarez-Lafuente R, Schroeder I, Zettl UK, Galimberti D, Ramió-Torrentà L, Robles R, Quintana E, Hegen H, Deisenhammer F, Río J, Tintoré M, Sánchez A, Montalban X, Comabella M.

Brain. 2018 Apr 1;141(4):1085-1093. doi: 10.1093/brain/awy021.

PMID:
29452342
13.

[Multiple sclerosis and hepatitis B vaccination : What does the verdict of the European Court of Justice on liability after vaccination mean?]

Löbermann M, Handorn B, Winkelmann A, Reisinger EC, Hartung HP, Zettl UK.

Nervenarzt. 2018 Feb 5. doi: 10.1007/s00115-018-0492-6. [Epub ahead of print] Review. German.

PMID:
29404651
14.

Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge.

Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS.

Expert Rev Clin Immunol. 2018 Feb;14(2):137-153. doi: 10.1080/1744666X.2018.1426462. Epub 2018 Jan 23.

PMID:
29318902
15.

Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine-1-phosphate receptor modulator.

Angerer IC, Hecker M, Koczan D, Roch L, Friess J, Rüge A, Fitzner B, Boxberger N, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Meister S, Zettl UK.

CNS Neurosci Ther. 2018 Mar;24(3):193-201. doi: 10.1111/cns.12793. Epub 2018 Jan 3.

PMID:
29314605
16.

Headache in the first manifestation of Multiple Sclerosis - Prospective, multicenter study.

Gebhardt M, Kropp P, Jürgens TP, Hoffmann F, Zettl UK.

Brain Behav. 2017 Nov 16;7(12):e00852. doi: 10.1002/brb3.852. eCollection 2017 Dec.

17.

Information processing deficits as a driving force for memory impairment in MS: A cross--sectional study of memory functions and MRI in early and late stage MS.

Köhler W, Fischer M, Bublak P, Faiss JH, Hoffmann F, Kunkel A, Sailer M, Schwab M, Stadler E, Zettl UK, Penner IK; HIPPOCOMS Study Group.

Mult Scler Relat Disord. 2017 Nov;18:119-127. doi: 10.1016/j.msard.2017.09.026. Epub 2017 Sep 25.

PMID:
29141793
18.

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Malhotra S, Sorosina M, Río J, Peroni S, Midaglia L, Villar LM, Álvarez-Cermeño JC, Schroeder I, Esposito F, Clarelli F, Zettl UK, Lechner-Scott J, Spataro N, Navarro A, Comi G, Montalban X, Martinelli-Boneschi F, Comabella M.

Mult Scler. 2017 Nov 1:1352458517739137. doi: 10.1177/1352458517739137. [Epub ahead of print]

19.

Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness.

Ehler J, Blechinger S, Rommer PS, Koball S, Mitzner S, Hartung HP, Leutmezer F, Sauer M, Zettl UK.

Int J Mol Sci. 2017 Aug 11;18(8). pii: E1749. doi: 10.3390/ijms18081749.

20.

CSF profile in primary progressive multiple sclerosis: Re-exploring the basics.

Abdelhak A, Hottenrott T, Mayer C, Hintereder G, Zettl UK, Stich O, Tumani H.

PLoS One. 2017 Aug 10;12(8):e0182647. doi: 10.1371/journal.pone.0182647. eCollection 2017.

21.

Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions.

Patejdl R, Zettl UK.

Autoimmun Rev. 2017 Sep;16(9):925-936. doi: 10.1016/j.autrev.2017.07.004. Epub 2017 Jul 8. Review.

PMID:
28698092
22.

Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis.

Friess J, Hecker M, Roch L, Koczan D, Fitzner B, Angerer IC, Schröder I, Flechtner K, Thiesen HJ, Winkelmann A, Zettl UK.

Sci Rep. 2017 Feb 3;7:42087. doi: 10.1038/srep42087.

23.

The Development of Sayk's Cell Sedimentation Chamber: A Historical View on Clinical Cerebrospinal Fluid Diagnostics.

Dahlmann N, Zettl UK, Kumbier E.

Eur Neurol. 2017;77(3-4):162-167. doi: 10.1159/000456003. Epub 2017 Jan 25.

24.

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.

Berger T, Elovaara I, Fredrikson S, McGuigan C, Moiola L, Myhr KM, Oreja-Guevara C, Stoliarov I, Zettl UK.

CNS Drugs. 2017 Jan;31(1):33-50. doi: 10.1007/s40263-016-0394-8. Review.

25.

[Diagnostic Workup and Treatment of Antibody-Related Encephalomyelitis].

Patejdl R, Winkelmann A, Ehler J, Zettl H, Meister S, Zettl UK.

Fortschr Neurol Psychiatr. 2016 Oct;84(S 02):S88-S91. Epub 2016 Nov 2. Review. German.

PMID:
27806422
26.

[Autoimmune-Mediated Encephalomyelitis: a Heterogeneous Entity in Between Neurology and Psychiatry].

Zettl UK, Dudesek A, Rimmele F, Zettl H, Patejdl R.

Fortschr Neurol Psychiatr. 2016 Oct;84(S 02):S84-S87. Epub 2016 Nov 2. Review. German.

PMID:
27806421
27.

Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.

Zettl UK, Schreiber H, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Hecker M; BETAPATH Study Group.

Acta Neurol Scand. 2017 Aug;136(2):116-121. doi: 10.1111/ane.12705. Epub 2016 Oct 30.

PMID:
27796033
28.

Hans Queckenstedt (1876-1918).

Kumbier E, Zettl UK.

J Neurol. 2017 May;264(5):1032-1034. doi: 10.1007/s00415-016-8315-9. Epub 2016 Oct 19. No abstract available.

PMID:
27761642
29.

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

Huss AM, Halbgebauer S, Öckl P, Trebst C, Spreer A, Borisow N, Harrer A, Brecht I, Balint B, Stich O, Schlegel S, Retzlaff N, Winkelmann A, Roesler R, Lauda F, Yildiz Ö, Voß E, Muche R, Rauer S, Bergh FT, Otto M, Paul F, Wildemann B, Kraus J, Ruprecht K, Stangel M, Buttmann M, Zettl UK, Tumani H.

J Neurol. 2016 Dec;263(12):2499-2504. Epub 2016 Oct 11.

30.

Analysis of microRNA and Gene Expression Profiles in Multiple Sclerosis: Integrating Interaction Data to Uncover Regulatory Mechanisms.

Freiesleben S, Hecker M, Zettl UK, Fuellen G, Taher L.

Sci Rep. 2016 Oct 3;6:34512. doi: 10.1038/srep34512.

31.

Comparative evaluation of patients' and physicians' satisfaction with interferon beta-1b therapy.

Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Hecker M; Study Group.

BMC Neurol. 2016 Sep 21;16(1):181.

32.

Neuromyelitis optica spectrum disorder coinciding with hematological immune disease: A case report.

Patejdl R, Wittstock M, Zettl UK, Jost K, Grossmann A, Prudlo J.

Mult Scler Relat Disord. 2016 Sep;9:101-3. doi: 10.1016/j.msard.2016.07.006. Epub 2016 Jul 8.

PMID:
27645353
33.

High-Resolution Expression Profiling of Peripheral Blood CD8+ Cells in Patients with Multiple Sclerosis Displays Fingolimod-Induced Immune Cell Redistribution.

Roch L, Hecker M, Friess J, Angerer IC, Koczan D, Fitzner B, Schröder I, Flechtner K, Thiesen HJ, Meister S, Winkelmann A, Zettl UK.

Mol Neurobiol. 2017 Sep;54(7):5511-5525. doi: 10.1007/s12035-016-0075-0. Epub 2016 Sep 8.

PMID:
27631876
34.

Coping with multiple sclerosis-the role of social support.

Rommer PS, Sühnel A, König N, Zettl UK.

Acta Neurol Scand. 2017 Jul;136(1):11-16. doi: 10.1111/ane.12673. Epub 2016 Sep 12.

PMID:
27620927
35.

Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.

Andlauer TF, Buck D, Antony G, Bayas A, Bechmann L, Berthele A, Chan A, Gasperi C, Gold R, Graetz C, Haas J, Hecker M, Infante-Duarte C, Knop M, Kümpfel T, Limmroth V, Linker RA, Loleit V, Luessi F, Meuth SG, Mühlau M, Nischwitz S, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Arloth J, Weber P, Radivojkov-Blagojevic M, Scheinhardt MO, Dankowski T, Bettecken T, Lichtner P, Czamara D, Carrillo-Roa T, Binder EB, Berger K, Bertram L, Franke A, Gieger C, Herms S, Homuth G, Ising M, Jöckel KH, Kacprowski T, Kloiber S, Laudes M, Lieb W, Lill CM, Lucae S, Meitinger T, Moebus S, Müller-Nurasyid M, Nöthen MM, Petersmann A, Rawal R, Schminke U, Strauch K, Völzke H, Waldenberger M, Wellmann J, Porcu E, Mulas A, Pitzalis M, Sidore C, Zara I, Cucca F, Zoledziewska M, Ziegler A, Hemmer B, Müller-Myhsok B.

Sci Adv. 2016 Jun 17;2(6):e1501678. doi: 10.1126/sciadv.1501678. eCollection 2016 Jun.

36.

Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.

Skierlo S, Rommer PS, Zettl UK.

Acta Neurol Scand. 2017 Apr;135(4):394-399. doi: 10.1111/ane.12612. Epub 2016 Jun 9.

PMID:
27283842
37.

Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.

Papathemeli D, Gräfe R, Hildebrandt U, Zettl UK, Ulrich J.

Mult Scler. 2016 Dec;22(14):1888-1890. Epub 2016 Apr 26.

PMID:
27207455
38.

Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients.

Sadovnick AD, Traboulsee AL, Bernales CQ, Ross JP, Forwell AL, Yee IM, Guillot-Noel L, Fontaine B, Cournu-Rebeix I, Alcina A, Fedetz M, Izquierdo G, Matesanz F, Hilven K, Dubois B, Goris A, Astobiza I, Alloza I, Antigüedad A, Vandenbroeck K, Akkad DA, Aktas O, Blaschke P, Buttmann M, Chan A, Epplen JT, Gerdes LA, Kroner A, Kubisch C, Kümpfel T, Lohse P, Rieckmann P, Zettl UK, Zipp F, Bertram L, Lill CM, Fernandez O, Urbaneja P, Leyva L, Alvarez-Cermeño JC, Arroyo R, Garagorri AM, García-Martínez A, Villar LM, Urcelay E, Malhotra S, Montalban X, Comabella M, Berger T, Fazekas F, Reindl M, Schmied MC, Zimprich A, Vilariño-Güell C.

G3 (Bethesda). 2016 Jul 7;6(7):2073-9. doi: 10.1534/g3.116.030841.

39.

Adherence to Long-Term Interferon Beta-1b Injection Therapy in Patients with Multiple Sclerosis Using an Electronic Diary.

Zettl UK, Bauer-Steinhusen U, Glaser T, Czekalla J, Hechenbichler K, Limmroth V, Hecker M.

Adv Ther. 2016 May;33(5):834-47. doi: 10.1007/s12325-016-0325-6. Epub 2016 Apr 18.

PMID:
27090116
40.

Disease-modifying therapies and infectious risks in multiple sclerosis.

Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK.

Nat Rev Neurol. 2016 Apr;12(4):217-33. doi: 10.1038/nrneurol.2016.21. Epub 2016 Mar 4. Review.

PMID:
26943779
41.

High-Density Peptide Microarray Analysis of IgG Autoantibody Reactivities in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.

Hecker M, Fitzner B, Wendt M, Lorenz P, Flechtner K, Steinbeck F, Schröder I, Thiesen HJ, Zettl UK.

Mol Cell Proteomics. 2016 Apr;15(4):1360-80. doi: 10.1074/mcp.M115.051664. Epub 2016 Feb 1.

42.

Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis.

Zettl UK, Rommer P, Hipp P, Patejdl R.

Ther Adv Neurol Disord. 2016 Jan;9(1):9-30. doi: 10.1177/1756285615612659. Review.

43.

Investigation of sex-specific effects of apolipoprotein E on severity of EAE and MS.

Schrewe L, Lill CM, Liu T, Salmen A, Gerdes LA, Guillot-Noel L, Akkad DA, Blaschke P, Graetz C, Hoffjan S, Kroner A, Demir S, Böhme A, Rieckmann P, ElAli A, Hagemann N, Hermann DM, Cournu-Rebeix I, Zipp F, Kümpfel T, Buttmann M, Zettl UK, Fontaine B, Bertram L, Gold R, Chan A.

J Neuroinflammation. 2015 Dec 16;12:234. doi: 10.1186/s12974-015-0429-y.

44.

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

Rommer PS, Dörner T, Freivogel K, Haas J, Kieseier BC, Kümpfel T, Paul F, Proft F, Schulze-Koops H, Schmidt E, Wiendl H, Ziemann U, Zettl UK; GRAID investigators.

J Neuroimmune Pharmacol. 2016 Mar;11(1):1-8. doi: 10.1007/s11481-015-9646-5. Epub 2015 Nov 20.

PMID:
26589235
45.

Multiple sclerosis and fatigue: A review on the contribution of inflammation and immune-mediated neurodegeneration.

Patejdl R, Penner IK, Noack TK, Zettl UK.

Autoimmun Rev. 2016 Mar;15(3):210-20. doi: 10.1016/j.autrev.2015.11.005. Epub 2015 Nov 14. Review.

PMID:
26589194
46.

Long-Term Effects of Repeated Cycles of Intrathecal Triamcinolone Acetonide on Spasticity in MS Patients.

Rommer PS, Kamin F, Abu-Mugheisib M, Koehler W, Hoffmann F, Winkelmann A, Benecke R, Zettl UK.

CNS Neurosci Ther. 2016 Jan;22(1):74-9. doi: 10.1111/cns.12474. Epub 2015 Nov 20.

PMID:
26584946
47.

Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.

Dankowski T, Buck D, Andlauer TF, Antony G, Bayas A, Bechmann L, Berthele A, Bettecken T, Chan A, Franke A, Gold R, Graetz C, Haas J, Hecker M, Herms S, Infante-Duarte C, Jöckel KH, Kieseier BC, Knier B, Knop M, Kümpfel T, Lichtner P, Lieb W, Lill CM, Limmroth V, Linker RA, Loleit V, Meuth SG, Moebus S, Müller-Myhsok B, Nischwitz S, Nöthen MM, Paul F, Pütz M, Ruck T, Salmen A, Stangel M, Stellmann JP, Strauch K, Stürner KH, Tackenberg B, Then Bergh F, Tumani H, Waldenberger M, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Hemmer B, Ziegler A; German Competence Network for Multiple Sclerosis (KKNMS).

Genet Epidemiol. 2015 Dec;39(8):601-8. doi: 10.1002/gepi.21933. Epub 2015 Oct 26.

PMID:
26497834
48.

Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.

Ahlbrecht J, Martino F, Pul R, Skripuletz T, Sühs KW, Schauerte C, Yildiz Ö, Trebst C, Tasto L, Thum S, Pfanne A, Roesler R, Lauda F, Hecker M, Zettl UK, Tumani H, Thum T, Stangel M.

Mult Scler. 2016 Aug;22(9):1202-14. doi: 10.1177/1352458515613641. Epub 2015 Oct 22.

PMID:
26493127
49.

Genome-wide significant association with seven novel multiple sclerosis risk loci.

Lill CM, Luessi F, Alcina A, Sokolova EA, Ugidos N, de la Hera B, Guillot-Noël L, Malhotra S, Reinthaler E, Schjeide BM, Mescheriakova JY, Mashychev A, Wohlers I, Akkad DA, Aktas O, Alloza I, Antigüedad A, Arroyo R, Astobiza I, Blaschke P, Boyko AN, Buttmann M, Chan A, Dörner T, Epplen JT, Favorova OO, Fedetz M, Fernández O, García-Martínez A, Gerdes LA, Graetz C, Hartung HP, Hoffjan S, Izquierdo G, Korobko DS, Kroner A, Kubisch C, Kümpfel T, Leyva L, Lohse P, Malkova NA, Montalban X, Popova EV, Rieckmann P, Rozhdestvenskii AS, Schmied C, Smagina IV, Tsareva EY, Winkelmann A, Zettl UK, Binder H, Cournu-Rebeix I, Hintzen R, Zimprich A, Comabella M, Fontaine B, Urcelay E, Vandenbroeck K, Filipenko M, Matesanz F, Zipp F, Bertram L.

J Med Genet. 2015 Dec;52(12):848-55. doi: 10.1136/jmedgenet-2015-103442. Epub 2015 Oct 16.

PMID:
26475045
50.

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β.

Bustamante MF, Morcillo-Suárez C, Malhotra S, Rio J, Leyva L, Fernández O, Zettl UK, Killestein J, Brassat D, García-Merino JA, Sánchez AJ, Urcelay E, Alvarez-Lafuente R, Villar LM, Alvarez-Cermeño JC, Farré X, Lechner-Scott J, Vandenbroeck K, Rodríguez-Antigüedad A, Drulovic JS, Martinelli Boneschi F, Chan A, Oksenberg J, Navarro A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e154. doi: 10.1212/NXI.0000000000000154. eCollection 2015 Oct.

Supplemental Content

Loading ...
Support Center